Nephrocare Health Services Limited (BOM:544647)
| Market Cap | 69.65B |
| Revenue (ttm) | 10.54B +39.4% |
| Net Income | 851.10M +26.8% |
| EPS | 8.63 +7.7% |
| Shares Out | n/a |
| PE Ratio | 81.83 |
| Forward PE | 40.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,144 |
| Open | 675.40 |
| Previous Close | 674.70 |
| Day's Range | 672.65 - 695.95 |
| 52-Week Range | 445.00 - 767.95 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 822.50 (+18.48%) |
| Earnings Date | Aug 11, 2026 |
About BOM:544647
Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India. [Read more]
Financial Performance
In fiscal year 2026, BOM:544647's revenue was 9.99 billion, an increase of 32.16% compared to the previous year's 7.56 billion. Earnings were 768.40 million, an increase of 14.52%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for 544647 stock is "Buy." The 12-month stock price target is ₹822.50, which is an increase of 18.48% from the latest price.
News
Nephrocare Health Services Transcript: Q1 26/27
Q1 FY 2027 saw 23.7% revenue growth and 31% adjusted EBITDA growth, driven by network expansion and higher international contribution. Utilization improved, ROCE reached 21%, and the company maintained 15%-20% medium-term growth guidance.
Nephrocare Health Services Quarterly report: Q1 2027
Nephrocare Health Services has published its Q1 2027 quarterly earnings report on August 12, 2026.
Nephrocare Health Services Slides: Q1 2027
Nephrocare Health Services has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 12, 2026.
Nephrocare Health Services Transcript: Q4 25/26
Revenue grew 32% YoY to INR 998.8 crore, with adjusted EBITDA up 37% and PAT up 75%, driven by international expansion and operational leverage. RPT rose 13.3% to INR 2,598, and ROCE improved to 22.8%. Guidance remains at 15%-20% CAGR over 3-4 years.
Nephrocare Health Services Quarterly report: Q4 2026
Nephrocare Health Services has published its Q4 2026 quarterly earnings report on May 20, 2026.
Nephrocare Health Services Annual report: Q4 2026
Nephrocare Health Services has published its Q4 2026 annual report on May 20, 2026.
Nephrocare Health Services Transcript: Q3 25/26
Revenue grew 32% YoY in Q3 and 37% for nine months FY 2026, with international business now 41% of revenue. Adjusted EBITDA margin rose to 24.3%, and ROCE is projected to reach 24.7%. Guidance is for 15%-20% revenue CAGR over 3-4 years.
Nephrocare Health Services Quarterly report: Q3 2026
Nephrocare Health Services has published its Q3 2026 quarterly earnings report on February 11, 2026.
Nephrocare Health Services Slides: Q3 2026
Nephrocare Health Services has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 11, 2026.
Nephrocare Health Services Quarterly report: H1 2026
Nephrocare Health Services has published its H1 2026 quarterly earnings report on December 8, 2025.